After a brief round of introductions, the panelists dove into the discussion, starting with their thoughts on the current state of point-of-care decision support tools. Carm gave a concise overview of Real-Time Prescription Benefit—the technology that enables providers to view patient cost and coverage information within the EHR—and spoke about how unreliable data has hindered adoption of these tools. He also shared his perspective on recent legislation that is driving the need for price transparency and interoperability capabilities. The panelists joined in by adding their thoughts about how policy changes are creating tailwinds for technology innovation, and how organizations of all types can help drive provider adoption of new prescribing technologies.
From there, the panelists took a deeper look at the two primary methods of delivering prescription data to the point-of-care: Formulary & Benefit (F&B) and Real-Time Prescription Benefit (RTPB) transactions. They made it abundantly clear that Real-Time Prescription Benefit is a superior method of data delivery because of its accuracy and timeliness. Additionally, they added, F&B does not allow for displaying of alternatives or robust reporting capabilities. As explained by Tom Groom, “we have to learn from what we’ve done in the past … RTPB is one way to make prescribing better for both patients and providers.” Carm added, “RTPB is able to show a price as if the patient was standing at the pharmacy counter…it’s that accurate.”
The panelists suggested three best practices for driving success with new prescription decision support tools:
- Remove inaccurate cost and coverage data from ePrescribing workflows to establish provider trust
- Provide meaningful, clinically relevant medication and pharmacy alternatives
- Normalize data and display information consistently for every patient
In order to achieve these best practices, the panelists recommended tactics including: limiting reliance on F&B and other methods that leverage historic or aggregated patient cost data, allowing multiple RTPB connections to increase patient coverage, and translating NDC and PBM codes for ease of use. They reiterated the fact that F&B hurt the industry’s perception of prescription data transactions, but with new methods, we can regain trust and drive utilization of these tools.
Finally, the panelists closed with their thoughts on the future of prescription decision support, from various innovations in RTPB, to the development of consumer-facing price transparency tools, to the highly anticipated streamlining of electronic prior authorization processes. The group agreed that if these predictions become reality, patient care would quickly become less costly and more personalized.
To watch the full discussion on demand, please click here. And to learn more about RxRevu, contact us today.